NTx Bio Advances Personalized Cancer Vaccine Manufacturing
Rio Rancho, New Mexico, August 19, 2026 NTx Bio is advancing the manufacturing infrastructure supporting personalized cancer vaccines through...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Rio Rancho, New Mexico, August 19, 2026 NTx Bio is advancing the manufacturing infrastructure supporting personalized cancer vaccines through...
BETHESDA, Md., July 2, 2026 Northwest Biotherapeutics announced that its Chief Technical Officer, Dr. Marnix Bosch, will deliver a...
SAN JOSE, Calif., June 29, 2026 Anixa Biosciences, Inc. announced that the Korean Ministry of Intellectual Property (MOIP) has...
SAN JOSE, Calif., June 11, 2026 Anixa Biosciences, Inc. announced that two of its clinical-stage cancer immunotherapy programs will...
NANTES, France, May 22, 2026 OSE Immunotherapeutics announced positive topline results from the Phase 2 TEDOVA trial evaluating Tedopi®...
Vancouver, British Columbia | January 20, 2026 — BioVaxys Technology Corp. reported positive Phase 1B/2 clinical results from its...
